Extended Data Fig. 8: Intra-tumoral injection of vivo-morpholino in H650 xenograft models.
From: Silent mutations reveal therapeutic vulnerability in RAS Q61 cancers
a, Images of KRAS-specific PCR amplicons generated from the cDNA of H650 xenograft tumors that were treated with daily intra-tumoral injection of morpholino for 7days. Fraction of exon 3 skipping is defined as the band intensities of “skipped/(skipped + full-length)” as measured by ImageJ (n = 1). M: 100 bp-marker. b, Fractions of exon 3 skipping in samples shown in (a) were compared using t test, **p < 0.01, n = 2–6 mice in each group, box plots show minimum, lower quartile, median, upper quartile, and maximum. c, Relative expression of KRAS exon 3 skipping, evaluated by qPCR in tumor samples corresponding to (a) (n = 3 biological replicates, mean ± s.e.m.). d, Body weight change of mice with H650 xenograft tumors treated with morpholino over time (n = 10 per each group, mean ± s.e.m.).
